Literature DB >> 17541257

Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy.

Jonathan Strosberg1, Sarah Hoffe, Nancy Gardner, Junsung Choi, Larry Kvols.   

Abstract

BACKGROUND/AIMS: The use of chemoradiation in the management of locally advanced pancreatic endocrine tumors has not been reported in the medical literature. Patients with unresectable tumors are often included in trials of systemic chemotherapy, and use of external beam radiation has been only described in few case reports. Given the sensitivity of pancreatic endocrine tumors to cytotoxic agents including streptozocin, doxorubicin and 5-FU, we have hypothesized that the combination of concurrent and sequential chemotherapy and radiation will yield higher response rates than acheivable with chemotherapy alone.
METHODS: Six patients with locally advanced pancreatic endocrine tumors were treated with a protocol consisting of radiation concurrent with infusional 5-FU (or capecitabine) along with induction and consolidation chemotherapy (streptozocin and doxorubicin). We retrospectively determined the objective radiographic response rate.
RESULTS: The objective response rate was 80%. With a median follow-up of 29 months, all six patients in the study have had continued reduction in tumor size from the time of the first posttreatment scan to the most recent scan. None of the patients have experienced local or metastatic disease progression. Treatment was well tolerated with minimal toxicity.
CONCLUSION: The combination of concurrent and sequential chemoradiotherapy appears to be a highly effective treatment for locally advanced pancreatic endocrine tumors. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541257     DOI: 10.1159/000102969

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  5 in total

1.  Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis.

Authors:  Zina Meriden; Chanjuan Shi; Barish H Edil; Trevor Ellison; Christopher L Wolfgang; Toby C Cornish; Richard D Schulick; Ralph H Hruban
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

2.  Anomer-equilibrated streptozotocin solution for the induction of experimental diabetes in mice (Mus musculus).

Authors:  Anabel S de la Garza-Rodea; Shoshan Knaän-Shanzer; Jan D den Hartigh; Alphons P L Verhaegen; Dirk W van Bekkum
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-01       Impact factor: 1.232

Review 3.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

4.  Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.

Authors:  Taymeyah Al-Toubah; Brian Morse; Jonathan Strosberg
Journal:  Curr Oncol       Date:  2022-01-26       Impact factor: 3.677

5.  Role of radiotherapy for pancreatobiliary neuroendocrine tumors.

Authors:  Jeongshim Lee; Jinhyun Choi; Chihwan Choi; Jinsil Seong
Journal:  Radiat Oncol J       Date:  2013-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.